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Platelet engraftment failure is a serious complication
leading to poor overall survival and quality of life in stem cell
transplantation. Neutrophil engraftment failure is usually
associated with failure of platelet engraftment. Relapse of
underlying disease such as acute leukemia can delay platelet
recovery. Because both of these situations aremajor causes of
poor survival, effect of platelet engraftment on survival is not
obvious in patients after neutrophil engraftment without
relapse.
We analyzed platelet engraftment in unrelated BMT (UR-
BMT), related BMT (Rel-BMT), related PBSCT (Rel-PBSCT),
and CBT using transplant outcome database of Japan Society
for Hematopoietic Cell Transplantation. Platelet engraftment
was deﬁned by the ﬁrst of three successive days with a non-
transfused platelet count of greater than 20x109/L. We
excluded cases with neutrophil engraftment failure or
relapse before achieving platelet engraftment, because both
of them can cause delay of platelet recovery. The study
population consisted of 12,101 patients who underwent UR-
BMT (3,482), Rel-BMT (3,153), Rel-PBSCT (2,834), or CBT
(2,632) for AML, ALL, CML, and MDS. The percentage of
platelet recovery (platelet count > 20x109/L, without trans-
fusion) in UR-BMT, Rel-BMT, Rel-PBSCT, and CBT was 89%,
94%, 93%, and 84%, and the median days of recovery after
transplantation was 28, 24, 18, and 44 days, respectively.
Multivariate Cox proportional hazards regression analysis
revealed that advanced stage of disease and poor perfor-
mance status ( grade 2) were common risk factors for
platelet engraftment failure in the four donor sources. Lower
cell dose was a signiﬁcant risk factor in UR-BMT and CBT.
HLA-mismatched graft was also signiﬁcant in the trans-
plantation other than CBT. We analyzed 1 year overall
survival in patients alive with or without platelet engraft-
ment every 10 days from 20 days to 100 days after trans-
plantation. Patients without platelet recovery showed
signiﬁcant poor survival than those with the recovery (Log-
rank test, p<0.001) at every point except day 20 in CBT. The
estimated 1 year overall survival of patients alive at day 100
with or without platelet recovery is 79% vs 62% (UR-BMT),
81% vs 62% (Rel-BMT), 72% vs 57% (Rel-PBSCT), 77% vs 57%
(CBT), and the probability of eventually achieving platelet
count>20x109/L in patients without recovery at day 100 was
25%, 31%, 34%, and 44%, respectively. Multivariate analysis
conﬁrmed that platelet recovery was signiﬁcantly associated
with survival.
In conclusion, platelet engraftment predicted overall
survival even excluding neutrophil engraftment failure and
early relapse in BMT, related PBSCT, and CBT.23
Superior Survival After Single Unit Umbilical Cord Blood
Transplantation (UCBT) in Children with Hematological
Malignancies Treated on Blood and Marrow Transplant
Clinical Trials Network (BMT CTN) 0501 Relative to the
Cord Blood Transplantation (COBLT)
Joanne Kurtzberg 1, Shelly L. Carter 2, Adam Mendizabal 2,
Donna A. Wall 3, Kirk R. Schultz 4, Nancy A. Kernan 5,Mary Eapen 6, John E. Wagner 7. 1 Pediatric Blood and Marrow
Transplant Program, Duke University Medical Center, Durham,
NC; 2 The EMMES Corporation, Rockville, MD; 3 CancerCare
Manitoba, Winnipeg, MB, Canada; 4 Department of Pediatric
Heme/Onc/BMT, 4480 Oak Str, BC Childrens Hospital,
Vancouver, BC, Canada; 5Memorial Sloan-Kettering Cancer Ctr,
New York, NY; 6 CIBMTR, Medical College of Wisconsin,
Milwaukee, WI; 7 Pediatric Blood and Marrow Transplantation,
University of Minnesota, Minneapolis, MN
We compared overall survival for recipients of a single
UCB unit treated for hematological malignancy on the COBLT
Study (n¼191) conducted from 1999-2004 to BMT CTN 0501
(n¼113) conducted from 2006-2012. The BMT CTN 0501 is
sponsored by NHLBI and NCI and, COBLT was sponsored by
NHLBI. Overall survival at 1-year was the primary endpoint
for both trials. Eligibility for both trials was similar with
a minimum total nucleated cell dose (TNC) of 2.5x107/kg for
BMT CTN and 1x107/kg for COBLT and HLA match of 4/6 at
antigen level for HLA A and B and allele level for HLA DRB1.
All patients received TBI 1350 cGy and cyclophosphamide
120 mg/kg. Patients enrolled on COBLT also received equine
ATG 90 mg/kg and those on BMT CTN 0501 ﬂudarabine
75mg/m2 with GVHD prophylaxis consisting of cyclosporine/
methyl prednisone and cyclosporine/mycophenolatemofetil,
respectively. The distribution of patient performance scores,
diseases, TNC (median dose: 4.8 x 107/kg for BMT CTN 0501
and COBLT, 5. 1 x 107/kg) and CD34 dose of the UCB units
were similar. Compared to those on BMT CTN 0501, patients
on COBLT were slightly younger (median age: 8 vs. 10 years,
p¼0.0007), more likely to be in relapse at transplant (16% vs.
5%, p¼0.0002) and less likely to receive a 5-6/6 HLA-matched
unit (29% vs. 59%, p<0.0001). The 1-year, the probabilities of
overall survival were 57% (95% CI 50 e 64) on COBLT and 71%
(95% CI 62 e 79) on BMT CTN 0501 (p¼0.01). In multivariate
analysis, mortality risks were higher for patients enrolled on
COBLT compared to those on BMT CTN 0501 (HR 1.82, 95% CI
1.19 e 2.78, p¼0.006). Mortality risks were also higher in
non-Caucasians independent of clinical trial (HR 1.95, 95%
1.32 e 2.88, p¼0.0007). The primary causes of death on both
trials were similar except for higher incidence of primary
graft failure on COBLT. The most frequent causes of death in
both treatment groups were recurrent leukemia and GVHD.
In summary, survival was better for patients treated on BMT
CTN 0501. Although it is not possible to prove which factor(s)
played the greatest role, it is the “package” including
conditioning and GVHD prophylactic regimens, supportive
care, method of unit selection and transplantation period
combined that contributed to the improved survival
observed in recipients of a single UCB unit in BMT CTN 0501.
Together, these results suggest the BMT CTN 0501 treatment
plan represents the new standard by which treatment
modiﬁcations will be compared.24
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Graft failure is a highly unsatisfactory outcome of allo-
geneic transplant. Several factors have been identiﬁed which
may predict for graft failure, however factors inﬂuencing the
success of a second allogeneic transplant in this setting are
not well studied.
Methods: The BSBMT analysed 130 patients receiving
a second allogeneic transplant for graft failure. Patients were
identiﬁed from the BSBMT Data Registry and transplant
centres were approached to provide follow up data.
Results: The median age of patients was 9 (range 4m-69),
with 53 (40%) being adults (>18). The disease was malignant
(47%) or non-malignant (53%). The majority of patients had
conditioning for the second transplant (68%), which included
serotherapy (Alemtuzumab/ATG) in almost all cases. This
was myeloablative (30%) or reduced intensity (39%)
(compared to 56% and 43%, respectively, at ﬁrst transplant).
The donor was a sibling (24%), unrelated donor (58%) or
other relative (18%). In 74% the same donor was used. The
stem cell source was bone marrow (41%), PBSC (54%), both
(2%) and UCB (3%) (compared to 53%, 38%, 1% and 7%,
respectively, at ﬁrst transplant). Stable engraftment occurred
in 88% of patients following the second transplant. Factors
associated with a signiﬁcant increase in engraftment failure
were older age (p¼0.003), male recipients (p¼0.025),
reduced intensity conditioning (compared to myeloablative
or none) (p¼0.031), the use of a different donor (p¼0.026)
and transplant for a malignant diagnosis (p¼0.005). Age
(HR¼11.52, p¼0.001) and the use of a different donor
(HR¼8.17, p¼0.003) remained signiﬁcant in the multivariate
analysis. The donor type, stem cell source and the time post
ﬁrst transplant did not impact on engraftment. Overall
survival was 60% at 5 years in the entire group. OS was
signiﬁcantly worse in adult patients (37% vs 74%, p<0.0001),
those with malignant disease (40% vs 78%, p¼0.0001) and
those transplanted beyond 3months after the ﬁrst transplant
(47% vs 65%, p¼0.02). No other factors tested were signiﬁ-
cant, and only malignancy remained signiﬁcantly associated
with OS in multivariate analysis (HR¼2.53, p¼0.018).
Conclusion: These encouraging results suggest that
successful engraftment and long term survival is possible
following a second transplant for graft failure. Although
outcomes are superior in children and those with non-
malignant disease, over a third of adult patients and those
with malignant diseases can also achieve long term survival.25
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The conﬁrmatory typing (CT) stage of unrelated donor
acquisition is a key source of delays to haematopoietic cell
provision. Identifying factors that might predict donor
deferral at this stage is important in reducing this delay and
improving patient outcome.
Methods: All CT requests made from Anthony Nolan
between 2010-11 were reviewed, and reason for deferral and
donor characteristics documented. Associations were deter-
mined using multivariate logistic regression analysis.Results: Of 7542 requests, 56.3% were completed, 38.2%
cancelled for donor reasons and 5.5% cancelled for transplant
centre reasons. Of donor cancellations 19.4% were personal,
34.1% medical, 36% no contact made, 7.9% overseas/
emigrated and 2.6% other. When compared to UK/North
European donors, African (OR 2.56, p¼0.001), Afro-Carib-
bean (OR 2.13, p<0.001), Asian (OR 2.45, p<0.001) and
Mediterranean donors (OR 1.93, p¼0.005) were more likely
to defer for donor reasons. Female donors were more likely
to defer for donor reasons (OR 1.19, p¼0.001), even when
pregnancy was excluded. This may be partly explained by
more medical deferrals (54% vs 46%). Donor age was also
associated with deferral, with more deferred aged 31-45 (OR
1.20, p¼0.002) and 46-60 (OR 1.43, p<0.001), compared to
18-30. This difference is largely explained by higher rates of
medical deferral (20.9% vs 34.6% vs 45.8% of all donor
cancellations for donors aged 18-30, 31-45 and 46-60
respectively), despite older donors being more easily con-
tacted, with fewer personal deferrals. Of medical deferrals,
19.4% of donors were deferred for morbid obesity (BMI>35),
14.4% for malignancy, 11.1% autoimmune conditions, 10.6%
cardiac, 5.3% back complaints and 7.1% diabetes. Blood
donors were less likely to be deferred for donor reasons (OR
0.72, p<0.001).
Conclusion: Despite over 20 million unrelated donors listed
on registers worldwide, high rates of donor attrition
considerably attenuate this resource and have a signiﬁcant
impact on donor provision. Donors from some ethnic
minorities have a particularly high rate of attrition. As
a registry, we are employing a number of strategies to
address the results of this study: increasing the base of
younger donors by reducing the joining age to 16-30, donor
pre-activation, use of social media to maintain contact with
donors and in depth interviews with those donors who
choose not to proceed.26
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Background: Allogeneic transplantation of haemopoietic
stem cells (HCT) from an HLA-matched related (MRD) or
unrelated donor (MUD) is a curative option for patients (pts)
affected by high-risk hematological diseases (HRHD). The
trend of growth of HCTs in adult pts with HRHD can be ex-
pected to continue based on acceptance and availability of
alternative donor. Few data are available for: i) the reliable
estimates of the number of HCT and the total number of pts
